Remove Compounding Remove Pharmaceutical Companies Remove Specialty Pharmacies
article thumbnail

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Pharmacy Times

This is progressing through a phase 3 trial and includes comparator arms with standard-of-care treatments like daratumumab, bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies), and lenalidomide. 2 We’re still trying to figure out where these new treatments best fit.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

In 2022, based upon a complaint filed by a pharmaceutical company, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. So, the pharmaceutical companies then pushed to get their 505(b)(2) drugs declared sole source,” Soefje said. “If This went into effect in January 2022.”

FDA 65
article thumbnail

Is Belantamab Mafodotin Making a Comeback?

Pharmacy Times

4,5 DREAMM-7 In DREAMM-7, patients with RRMM who had received at least 1 prior line of therapy were randomized 1:1 to receive belantamab mafodotin plus bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies) and dexamethasone (BVd) compared with daratumumab (Darzalex; Johnson & Johnson), bortezomib, and dexamethasone (DVd).